Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Poland / NCT07511959
Enrolling by invitation Observational

Autologous Exosomes From Platelet-rich Plasma as a Modern Tool of Regenerative Dentistry

NCT07511959 · tracked via the Priya Life Science Poland tracker
Sponsor
Wroclaw Medical University
Phase
Observational
Started
2026-05-01
Last updated
2026-07-13

Condition(s) studied

Temporomandibular Disorders (TMD)Muscle PainTMJ Pain

Investigational drug(s) / intervention(s)

Laboratory analysis of the content and biological activity of PRP, PRF, and exosomes obtained from blood samples

Laboratory analysis of the content and biological activity of PRP, PRF, and exosomes obtained from blood samples: Laboratory analysis include in vitro tests aimed to: (1) evaluation of the size and concentration of exosomes, (2) the measurement of the level of cytokines and growth factors in the samples of PRP, PRF and EXO, (3) comparison of the impact of exosomes, PRF and PRP (from the study and control groups) on the proliferation and migration of human chondrocytes and fibroblasts.

Study summary

The aim of the research is the laboratory assessment of the content as well as the regenerative and anti-inflammatory potential of autologous exosomes (EXO) from platelet-rich plasma (PRP), as well as their comparison with other autologous products used in intra-articular injections, namely platelet-rich plasma and platelet-rich fibrin (PRF).

The material for the research will be obtained from patients of the Temporomandibular Joint Dysfunction Clinic at the University Dental Center in Wrocław with chronic pain of the temporomandibular joints (TMJ) and/or masticatory muscles and/or chronic disturbances in temporomandibular joint mobility, as well as from healthy individuals.

In the subsequent stages, the biological material will be analyzed under laboratory conditions to compare the composition and biological properties of PRP, PRF and EXO.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * chronic pain of the temporomandibular joints and/or masticatory muscles and/or chronic dysfunction of the temporomandibular joints (lasting more than 3 months, diagnosed based on the standardized, international Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) protocol) - criterion for the study group * consent to participate in the study - criterion for both groups * age over 18 years - criterion for both groups Exclusion Criteria: * cancer, * pregnancy * uncontrolled diabetes * cardiovascular diseases (platelet dysfunction syndrome, critical thrombocytopenia, hemodynamic instability, sepsis, hemoglobin \< 10 g/dl, platelet count \< 105/µl) * severe autoimmune diseases * taking anticoagulants * active skin lesions at the planned puncture site * infections, patient undergoing antibiotic therapy, or within 3 weeks of its completion.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Wroclaw Medical Uniwesity, Wroclaw Wroclaw Poland

More Wroclaw Medical University trials in Poland

The Impact of Expandable Cryoballoon on Autonomic Control of the Heart Active, not recruiting
Effectiveness of iPRF Injections in Temporomandibular Joints Degeneration Management Enrolling by invitation
Selected Disorders and Sleep Bruxism Enrolling by invitation
Concentration of Receptors With Affinity for Cannabidiol and Cannabinol and the Effect on Chronic Orofacial Pain of Muscle Origin Enrolling by invitation
Evaluation of the Factors Associated With BRADYcardia Following Pulmonary Vein Isolation Using Pulsed Field Ablation Recruiting

Other trials for the same condition

Concentration of Receptors With Affinity for Cannabidiol and Cannabinol and the Effect on Chronic Orofacial Pain of Muscle Origin Enrolling by invitation
The Effectiveness of CBD and CBN in the Treatment of Facial Pain and Headache of Muscular Origin Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07511959 on ClinicalTrials.gov ↗ ← All trials in Poland